Over-activation of EFTUD2 correlates with tumor propagation and poor survival outcomes in hepatocellular carcinoma

Lv, Chao; Li, X J; Hao, Liyuan; Zhang, S; Song, Zhuo; Ji, Xuechun; Gong, Bo

doi:10.1007/s12094-021-02673-y

Cited by 11 publications

(12 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…. In hepatic cellular cancer, EFTUD2 was upregulated compared to healthy liver tissue(Lv, Li et al 2021). In analogy to our results in EC, a negative correlation between survival rates and EFTUD2 expression was shown.…”

supporting

confidence: 86%

See 1 more Smart Citation

High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer

Beyer

Müller

Mitter

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose Endometrial cancer is the most common gynecological malignancy. The helicase RIG-I, a part of the innate immune system, and EFTUD2, a splicing factor which can upregulate RIG-I expression, are shown to influence tumor growth and disease progression in several malignancies. For endometrial cancer, an immunogenic cancer, data about RIG-I and EFTUD2 are still missing. The aim of this study was to examine the expression of RIG-I and EFTUD2 in endometrial cancer. Methods 225 specimen of endometrial cancer were immunohistochemically stained for RIG-I and EFTUD2. The results were correlated to clinicopathological data, overall survival (OS) and progression-free survival (PFS). Results High RIG-I expression correlated with advanced tumor stages (FIGO: p = 0.027; pT: p = 0.010) and worse survival rates (OS: p = 0.009; PFS: p = 0.022). High EFTUD2 expression correlated to worse survival rates (OS: p = 0.026; PFS: p < 0.001) and was determined to be an independent marker for survival rates. Conclusion Our data suggest that the expression of RIG-I and EFTUD2 correlates with survival data, which makes both a possible therapeutic target in the future.

show abstract

supporting

confidence: 86%

mentioning

confidence: 96%

High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer

Beyer

Müller

Mitter

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…In analogy to our results in EC, a negative correlation between survival rates and EFTUD2 expression was shown. Also, a reduced tumor growth in case of EFTUD2 knockdown was detected, suggesting it as an independent prognostic factor for patients with hepatic cellular cancer (Tu et al 2020;Lv et al 2021). Furthermore, another limitation of this study needs to be discussed: although the data regarding FIGO/pT/grade and survival rates are consistent and clear, RIG-I expression did not turn out to be an independent marker for survival.…”

Section: Discussionmentioning

confidence: 74%

High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer

Beyer

Müller

Mitter

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Endometrial cancer is the most common gynecological malignancy. The helicase RIG-I, a part of the innate immune system, and EFTUD2, a splicing factor which can upregulate RIG-I expression, are shown to influence tumor growth and disease progression in several malignancies. For endometrial cancer, an immunogenic cancer, data about RIG-I and EFTUD2 are still missing. The aim of this study was to examine the expression of RIG-I and EFTUD2 in endometrial cancer. Methods 225 specimen of endometrial cancer were immunohistochemically stained for RIG-I and EFTUD2. The results were correlated to clinicopathological data, overall survival (OS) and progression-free survival (PFS). Results High RIG-I expression correlated with advanced tumor stages (FIGO: p = 0.027; pT: p = 0.010) and worse survival rates (OS: p = 0.009; PFS: p = 0.022). High EFTUD2 expression correlated to worse survival rates (OS: p = 0.026; PFS: p < 0.001) and was determined to be an independent marker for progression-free survival. Conclusion Our data suggest that the expression of RIG-I and EFTUD2 correlates with survival data, which makes both a possible therapeutic target in the future.

show abstract

“…Further study to investigate the molecular mechanism of possible link between cell proliferation and migration regulated by EFTUD2 in GC is warranted. A study of EFTUD2 revealed that it plays a pivotal role in HCC cell proliferation and the cell cycle [29] , meanwhile another report [30] that EFTUD2 as a novel oncogene that helps to maintain the survival of HCC cells and promotes HCC progression. The high level of expression of EFTUD2 in HCC tissues indicates shorter overall and recurrence-free survival in HCC patients.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Biomarkers Based On GUF1, EFTUD2 and GSPT1 Targets Affecting Migration of Gastric Cancer Cells.

Wang

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

Eukaryotic Elongation Factor 1 Alpha 2 (EEF1A2) is a protein coding gene which involved in tumor development and progression in several types of human cancer, but little is known about the function of EEF1A2 proteins in gastric cancer (GC).The ONCOMINE and the TCGA databases were used to evaluate the expression of GUF1, EFTUD2, GSPT1 and GSPT2 in GC and the association of EEF1A2 family with individual clinical characteristics. Kaplan-Meier (K-M) Plotter hint the prognostic value of GUF1, EFTUD2, GSPT1 and GSPT2. GSE62254 and GSE66222 dataset were used to validated the expression of GUF1, EFTUD2, GSPT1. Human AGS and GES cells lines were also used for validating the function of GUF1, EFTUD2, GSPT1. RNA interference (RNAi) of GUF1, EFTUD2 and GSPT1 have been used to query those genes expression pattern and dissect the proliferation and migration in GC cells line. The results showed that GUF1, EFTUD2 and GSPT1 were significantly up-regulated in GC cell lines. High expression of GUF1, EFTUD2 and GSPT1 was correlated with cell proliferation and migration induced in GC cells. We report GUF1, EFTUD2 and GSPT1 may be potential novel oncogenes that helps to maintain the survival of GC cells. Our study identified that high level of GUF1, EFTUD2 and GSPT1 expression are predictive biomarkers for a poor prognosis in GC.

show abstract

Over-activation of EFTUD2 correlates with tumor propagation and poor survival outcomes in hepatocellular carcinoma

Cited by 11 publications

References 44 publications

High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer

High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer

High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer

Prognostic Biomarkers Based On GUF1, EFTUD2 and GSPT1 Targets Affecting Migration of Gastric Cancer Cells.

Contact Info

Product

Resources

About